Outset Medical (Nasdaq: OM) announced today that the FDA says it addressed all issues cited in a 2023 warning letter.

Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.

Outset Medical (OM) announced it has been notified by the FDA that all issues cited in a warning letter the company received in July of 2023 ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

NKGen Biotech (NKGN) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, for the investigation ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Q4 2024 Earnings Call Transcript February 11, 2025 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.48 EPS, ...

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Q1 2025 Earnings Call Transcript February 12, 2025 NeuroOne Medical Technologies Corporation beats earnings expectations. Reported EPS is ...

In this article, we will discuss the 12 Best Healthcare Stocks to Buy According to Analysts. McKinsey reported that, since ...

Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: ...